Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Lancet Neurology
Juan ForteaAlberto Lleó

Abstract

Diagnosis of Alzheimer's disease in Down syndrome is challenging because of the absence of validated diagnostic biomarkers. We investigated the diagnostic performance of plasma and CSF biomarkers in this population. We did a cross-sectional study of adults aged 18 years and older with Down syndrome enrolled in a population-based health plan in Catalonia, Spain. Every person with Down syndrome assessed in the health plan was eligible to enter the Down Alzheimer Barcelona Neuroimaging Initiative, and those with a plasma or CSF sample available were included in this study. Participants underwent neurological and neuropsychological examination and blood sampling, and a subset underwent a lumbar puncture. Adults with Down syndrome were classified into asymptomatic, prodromal Alzheimer's disease, or Alzheimer's disease dementia groups by investigators masked to biomarker data. Non-trisomic controls were a convenience sample of young (23-58 years) healthy people from the Sant Pau Initiative on Neurodegeneration. Amyloid-β (Aβ)1-40, Aβ1-42, total tau (t-tau), 181-phosphorylated tau (p-tau; only in CSF), and neurofilament light protein (NfL) concentrations were measured in plasma with a single molecule array assay and in CSF with ELISA....Continue Reading

Citations

Dec 12, 2018·Developmental Neurobiology·Michael S Rafii
Jul 7, 2019·Developmental Neurobiology·María Carmona-IraguiJuan Fortea
Jul 28, 2019·Developmental Neurobiology·Eric D HamlettAnn-Charlotte Granholm
Aug 8, 2019·Developmental Neurobiology·Falah AlhajrafAndre Strydom
Oct 28, 2019·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Daniel AlcoleaAlberto Lleó
Jan 23, 2020·Brain Sciences·Kate L LambertsenHelle H Nielsen
Dec 26, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·André StrydomHenrik Zetterberg
Nov 2, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Andréa L BenedetPedro R Neto
Jan 22, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Grace E WeberLynn M Bekris
Feb 13, 2020·Current Opinion in Psychiatry·Eimear McGlincheyMary McCarron
May 26, 2020·American Journal of Medical Genetics. Part a·Angelo CarfìGraziano Onder
Jun 10, 2020·Annals of Clinical and Translational Neurology·Fen HuangJames D Berry
Jun 17, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Heather M SnyderMichael S Rafii
Sep 26, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Xu-Qiao ChenWilliam C Mobley
Mar 25, 2019·Alzheimer's Research & Therapy·Carla M StartinAndré Strydom
Jan 4, 2020·Therapeutic Advances in Neurological Disorders·Marta Milà-AlomàJosé Luís Molinuevo
Jul 7, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Melissa E PetersenUNKNOWN Alzheimer's Biomarker Consortium – Down Syndrome (ABC‐DS)
May 22, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Melissa PetersenSid E O'Bryant
Jul 17, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Rachel L HensonAnne M Fagan
Aug 8, 2019·Developmental Neurobiology·Melissa E Petersen, Sid E O'Bryant
Aug 16, 2019·Cellular and Molecular Neurobiology·Agustín RiquelmeGloria Benítez-King
Jun 4, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Sid E O'BryantNicole Schupf
Apr 8, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Mark MapstoneUNKNOWN Alzheimer's Biomarkers Consortium–Down Syndrome (ABC‐DS) Investigators
Feb 8, 2020·Nature Reviews. Disease Primers·Stylianos E AntonarakisRoger H Reeves
Jul 16, 2020·Medicine·Roqayeh GashmardSima Mohammad Khan Kermanshahi
Aug 15, 2020·Scientific Reports·David de Gonzalo-CalvoMireia Tondo
Jul 3, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Bessy BenejamJuan Fortea
Apr 24, 2020·Nature Reviews. Neurology·Nicholas J AshtonDag Aarsland
Oct 19, 2020·Brain Imaging and Behavior·Katherine A KoenigJames B Leverenz
Nov 24, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Rowan PentzA Claudio Cuello
Dec 19, 2020·Journal of Alzheimer's Disease : JAD·Melissa E PetersenUNKNOWN Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS)
Nov 3, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Michael S RafiiSid O'Bryant
Jul 11, 2019·Contemporary Clinical Trials Communications·Arinjita Bhattacharyya, Shesh N Rai
Nov 19, 2020·Brain : a Journal of Neurology·Lisi Flores-AguilarA Claudio Cuello
Feb 4, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Mélanie BrissonJean-Paul Soucy
Nov 3, 2020·Frontiers in Aging Neuroscience·Yang XiangYongjian Yang
Oct 23, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Alessandra C MartiniElizabeth Head

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
G G KovacsKaj Blennow
Revista de derecho y genoma humano = Law and the human genome review
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Everard G B VijverbergYolande A L Pijnenburg
© 2022 Meta ULC. All rights reserved